KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Finished Goods: 2018-2024

Historic Finished Goods for Alnylam Pharmaceuticals (ALNY) over the last 7 years, with Dec 2024 value amounting to $26.4 million.

  • Alnylam Pharmaceuticals' Finished Goods rose 67.99% to $38.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.9 million, marking a year-over-year increase of 67.99%. This contributed to the annual value of $26.4 million for FY2024, which is 5.21% up from last year.
  • According to the latest figures from FY2024, Alnylam Pharmaceuticals' Finished Goods is $26.4 million, which was up 5.21% from $25.1 million recorded in FY2023.
  • Alnylam Pharmaceuticals' Finished Goods' 5-year high stood at $26.4 million during FY2024, with a 5-year trough of $7.0 million in FY2021.
  • Over the past 3 years, Alnylam Pharmaceuticals' median Finished Goods value was $25.6 million (recorded in 2022), while the average stood at $25.7 million.
  • In the last 5 years, Alnylam Pharmaceuticals' Finished Goods spiked by 378.08% in 2020 and then crashed by 44.81% in 2021.
  • Yearly analysis of 5 years shows Alnylam Pharmaceuticals' Finished Goods stood at $12.7 million in 2020, then slumped by 44.81% to $7.0 million in 2021, then soared by 265.54% to $25.6 million in 2022, then decreased by 1.89% to $25.1 million in 2023, then grew by 5.21% to $26.4 million in 2024.